Results 21 to 30 of about 2,259 (131)

An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study

Clinical and Translational Science, 2022
Inclisiran is a small interfering RNA molecule that has been shown to provide an effective and sustained reduction in low‐density lipoprotein cholesterol levels.
David Kallend, Jay Mason, Patrick F. Smith, Michael J. Koren, Robert Stoekenbroek, YanLing He, Peter Wijngaard   +6 more
doaj   +1 more source

EFFICACY AND SAFETY OF INCLISIRAN BY BASELINE BODY MASS INDEX: A POST HOC POOLED ANALYSIS OF THE ORION-9, ORION-10 AND ORION-11 PHASE III RANDOMIZED CONTROLLED TRIALS

American Journal of Preventive Cardiology, 2023
Therapeutic Area: ASCVD/CVD Risk Factors Background: Excessive bodyweight, often associated with dyslipidemia, may affect the pharmacology of drugs. Inclisiran, a small interfering RNA targeting PCSK9 hepatic mRNA, is an effective LDL-C lowering agent ...
Lawrence A Leiter, David G Kallend, Wolfgang Koenig, Ulf Landmesser, Kausik K Ray, Gregory G Schwartz, R Scott Wright, YannTong Chiang, Lorena Garcia Conde Orozco, Frederick J Raal   +9 more
doaj   +1 more source

Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies

American Heart Journal Plus, 2022
Study objective: This systematic review and meta-analysis aimed to assess the efficacy and safety profile of treatment with inclisiran, a drug that has been recently approved by the United States Food and Drug Administration (FDA) and the European ...
Arrigo F.G. Cicero, Federica Fogacci, Alberto Zambon, Peter P. Toth, Claudio Borghi   +4 more
doaj   +1 more source

Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review

Cardiovascular Therapeutics, 2022
As dyslipidemias remain one of the main risk factors for developing cardiovascular disease, the question of maintaining optimal lipid levels with pharmacotherapy remains a subject of interest worldwide.
Iveta Merćep, Nikolina Friščić, Dominik Strikić, Željko Reiner   +3 more
doaj   +1 more source

A RANDOMIZED STUDY TO COMPARE LDL-C-LOWERING EFFECTS OF INCLISIRAN WITH USUAL CARE VS USUAL CARE ALONE IN PATIENTS WITH RECENT HOSPITALIZATION FOR AN ACUTE CORONARY SYNDROME: RATIONALE AND DESIGN OF THE VICTORION-INCEPTION TRIAL

American Journal of Preventive Cardiology, 2023
Therapeutic Area: CVD Prevention – Primary and Secondary Background: Patients are at high risk for a recurrent cardiovascular (CV) event in the first year following acute coronary syndrome (ACS).
Jeffrey L. Anderson, MD, Ann Marie Navar, MD, PhD, Neeraja Balachander, MBBS, PhD, MS, Nihar R. Desai, MD, MPH, Kirk U. Knowlton, MD   +4 more
doaj   +1 more source

Inclisiran - hope in the fight against dyslipidemia

Journal of Education, Health and Sport, 2023
Introduction:Lipid disorders are one of the most common modifiable risk factors for cardiovascular disease. Until now, the mainstay of dyslipidemia treatment was the use of widely available statins.
Paulina Krawiec, Karolina Madej, Izabela Wolanin, Bartłomiej Zielonka, Ilona Kowalczyk, Bartłomiej Stachyra, Marta Wolanin, Cezary Stawikowski, Barbara Dengler, Aleksandra Osińska   +9 more
doaj   +1 more source

Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis [PDF]

Journal of Clinical Medicine, 2021
The reduction of circulating low-density lipoprotein-cholesterol (LDL-C) is a primary target in cardiovascular risk reduction due to its well-established benefits in terms of decreased mortality. Despite the use of statin therapy, 10%–20% of high- and very-high-risk patients do not reach their LDL-C targets.
Sylwester Rogula, Ewelina Błażejowska, Aleksandra Gąsecka, Łukasz Szarpak, Milosz J. Jaguszewski, Tomasz Mazurek, Krzysztof J. Filipiak   +6 more
openaire   +2 more sources

Inclisiran (Leqvio)

Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire   +2 more sources

Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials

Frontiers in Pharmacology, 2023
Aims: As the impact of inclisiran in stroke prevention in atherosclerotic cardiovascular disease (ASCVD) patients or those at high risk of ASCVD is still unclear, we conducted a systematic review and meta-analysis of randomized controlled trials (RCT) to
Min Luo, Yihan Liu, Yihan Liu, Xinyi Xu, Xinyi Xu, Kai Liu, Chao Shen, Haoyang Hu, Zhiyao He, Fengbo Wu   +9 more
doaj   +1 more source

Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders

Российский кардиологический журнал, 2023
The novelty of the 2023 National Guidelines for Lipid Metabolism Disorders is presented regarding the categorization of cardiovascular risk, target and optimal levels of blood lipids, diagnosis and therapeutic approaches to the treatment of dyslipidemia.
I. V. Sergienko, M. V. Ezhov
doaj   +1 more source